Thailand Blood Plasma Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Blood Plasma Market Size

• The Thailand blood plasma market size was valued at USD 134 million in 2024 and is expected to reach USD 220.11 million by 2032, at a CAGR of 6.40% during the forecast period
• The market growth is largely fueled by the adoption of advanced technologies in plasma collection, processing, and fractionation, aimed at improving product quality, safety, and yield
• Furthermore, growing demand for plasma-derived therapies, especially immunoglobulins and clotting factors are also fuelling market growth

Blood Plasma Market Analysis

• Blood plasma-derived products are essential for treating a wide range of life-threatening conditions, including immune deficiencies, hemophilia, and neurological and autoimmune disorders. In Thailand, the growing burden of chronic diseases, increasing healthcare access, and government efforts to strengthen plasma collection and self-sufficiency are key factors driving the market expansion
• The rising demand for plasma-derived therapies is fueled by an aging population, increasing prevalence of rare and chronic conditions, and the expanding application of immunoglobulin and coagulation factors in critical care and post-transplant treatments.
• Hyperimmune globulin is expected to dominate the Thailand blood plasma market with a market share of 32.8.5 in 2024, driven by its specialized use in emerging infectious diseases such as COVID-19 and dengue, both of which are prevalent in the region. The government’s interest in emergency preparedness and immunization programs further supports the segment’s growth

Report Scope and Blood Plasma Market Segmentation        

Blood Plasma Market Trends

“Technological Advancements and Increasing Plasma Fractionation Capacity”

• A prominent and growing trend in the Thailand blood plasma market is the adoption of advanced technologies in plasma collection, processing, and fractionation, aimed at improving product quality, safety, and yield. This trend is driven by the increasing demand for plasma-derived therapies to address chronic and rare diseases in the region
• For instance, in 2023, Bangkok-based plasma centers upgraded their collection systems with modern apheresis machines that enhance donor comfort and increase plasma yield, supporting the rising need for immunoglobulins and clotting factors
• Thailand’s key plasma fractionation facilities are investing in next-generation purification technologies such as chromatography and viral inactivation methods, complying with global quality standards and ensuring safer plasma-derived medicinal products (PDMPs) for both domestic use and export
• The government and private sector collaborations are also accelerating capacity expansion projects to reduce plasma product shortages, with several plasma collection centers expanding their donor base through awareness campaigns and improved donor screening processes
• Furthermore, digital solutions like donor management software and traceability systems are being increasingly implemented to optimize plasma collection logistics and maintain compliance with regulatory frameworks enforced by the Thai Food and Drug Administration (FDA)
• Emerging R&D efforts in Thailand focus on developing innovative plasma therapies for autoimmune and rare genetic disorders, positioning the country as a potential hub for specialized plasma products in Southeast Asia
• This trend of technological modernization and capacity enhancement is strengthening Thailand’s plasma market infrastructure, improving patient access to critical therapies, and fostering growth opportunities for domestic and international plasma product manufacturer

Blood Plasma Market Dynamics

Driver

“Growing Demand for Plasma-Derived Therapies and Government Support”

• The rising prevalence of chronic and rare diseases such as immunodeficiencies, hemophilia, and neurological disorders in Thailand is significantly driving the demand for plasma-derived medicinal products (PDMPs) like immunoglobulins, clotting factors, and albumin
• For instance, the World Health Organization (WHO) reports that plasma-derived therapies are essential for treating over 80 rare and chronic conditions, many of which are increasingly diagnosed in Thailand due to improved healthcare access and awareness
• The Thai government is actively supporting the development of the domestic plasma industry by implementing favorable policies, funding plasma collection programs, and strengthening regulatory frameworks through the Thai Food and Drug Administration (FDA) to ensure the quality and safety of plasma products
• In response, hospitals and healthcare providers are expanding their use of PDMPs, and plasma centers are increasing their collection capacities to meet this growing clinical demand, helping improve patient outcomes
• Thus , public-private partnerships and awareness campaigns to encourage plasma donation are further boosting the supply side, aligning with the country’s goal to reduce dependence on imported plasma products and enhance self-sufficiency

Restraint/Challenge

“Limited Plasma Donation Rates and High Processing Costs”

• The blood plasma market in Thailand faces significant challenges due to low plasma donation rates, which restrict the availability of raw plasma needed for the production of plasma-derived therapies. Cultural hesitancy, lack of donor awareness, and limited donor centers contribute to this constraint
• For instance, according to the World Health Organization (WHO), plasma donation rates in Southeast Asia, including Thailand, remain below the levels seen in Western countries, creating a supply-demand gap for plasma products and impacting market growth
• Additionally, the high costs associated with plasma collection, screening, and fractionation technology limit the expansion of plasma product manufacturing in Thailand Investments in advanced processing facilities and stringent quality controls require substantial capital, which can be a barrier for local companies
• Furthermore, regulatory complexities and compliance with international standards for plasma safety increase operational expenses and slow down market entry for new players
• This challenge is compounded by the reliance on imported plasma products and raw materials, which can be subject to supply chain disruptions and fluctuating costs, thereby affecting the pricing and accessibility of plasma therapies within the country

Blood Plasma Market Scope

The market is segmented on the basis of type, mode of delivery, therapeutic indication, application, and end-users.

• By Type

On the basis of type, the Thailand blood plasma market is segmented into hyperimmune globulin, albumin, factor VIII, factor IX, immunoglobulin, and others. The hyperimmune globulin segment dominates the market with the largest revenue share of approximately 34.7% in 2024, driven by its critical role in treating infectious diseases such as rabies, tetanus, and hepatitis in Thailand. This segment’s dominance is further supported by government initiatives to improve access to plasma therapies and rising awareness among healthcare professionals and patients.

The albumin segment is anticipated to witness the fastest growth rate from 2025 to 2032, propelled by its expanding use in volume replacement therapies during surgeries, trauma care, and liver diseases, aligned with the growth of Thailand’s healthcare infrastructure and rising surgical procedures.

• By Mode of Delivery

On the basis of mode of delivery, the Thailand blood plasma market is segmented into infusion solutions, gels, sprays, and biomedical sealants. The infusion solutions segment holds the largest market share in 2024, due to its widespread application in intravenous therapies for immunodeficiency and bleeding disorders.

The gels segment is projected to grow at the fastest CAGR of 9.7% from 2025 to 2032, driven by increasing use in wound management and surgical applications, supported by innovations in biomedical materials and rising demand in healthcare facilities.

• By Therapeutic Indication

Based on therapeutic indication, the market is segmented into immunology, oncology, pulmonology, rheumatology, transplantation, neurology, hematology, and others. The immunology segment dominates the market with the largest market share in 2024, due to the increasing prevalence of immunodeficiency disorders and autoimmune diseases in Thailand.

The oncology segment is expected to witness the fastest growth rate from 2025 to 2032, fueled by rising cancer incidence and enhanced use of plasma-derived products in cancer supportive care and treatment.

• By Application

On the basis of application, the market is segmented into hypogammaglobulinemia, immunodeficiency diseases, hemophilia, Von Willebrand's Disease (vWD), and others. The immunodeficiency diseases segment holds the largest revenue share of approximately 40.3% in 2024, supported by improved diagnostic capabilities and government programs promoting plasma therapy accessibility.

The hemophilia segment is projected to register the highest CAGR over 2025 to 2032, driven by increasing patient awareness and availability of factor replacement therapies.

• By End User

The market is segmented into clinics, hospitals, and others. The hospitals segment leads with a dominant revenue share in 2024, reflecting the advanced healthcare infrastructure and increasing adoption of blood plasma therapies in hospital settings.

The clinics segment is forecast to grow at the highest CAGR from 2025 to 2032, as outpatient care and home-based plasma treatment models gain traction in Thailand.

Thailand Blood Plasma Market Insight

The Thailand blood plasma market is projected to account for approximately 12.8.5 of the Southeast Asia regional market revenue in 2024, supported by rising healthcare awareness, expanding government initiatives for plasma donation, and increasing prevalence of chronic and immune-related diseases. The demand is particularly strong in major urban centers such as Bangkok, Chiang Mai, and Phuket, where advanced healthcare facilities and specialized treatment centers are driving higher consumption of plasma-derived therapies. Government efforts to improve plasma collection infrastructure and regulatory frameworks aimed at ensuring safety and quality of plasma products are further bolstering market growth. Additionally, growing public education campaigns on the benefits of plasma donation and the rising number of plasma centers are encouraging higher donor participation. The hospital sector, especially tertiary care and specialty clinics, is witnessing increased adoption of plasma-based treatments, supported by expanding insurance coverage and rising patient affordability.

Blood Plasma Market Share

The blood plasma industry is primarily led by well-established companies, including:

• Grifols SA Ordinary Shares - Class A (Spain)
• CSL Ltd (Australia)
• Takeda Pharmaceutical Co Ltd (Japan)
• Biotest AG ADR (Germany)
• Octapharma AG (Switzerland)
• Kedrion Biopharma (Italy)
• LFB (Laboratoire Français du Fractionnement et des Biotechnologies) (France)
• Bio Products Laboratory (U.K.)
• Intas Pharmaceuticals (India)
• HUGEL, Inc. (South Korea)
• Ipsen Pharma (France)
• USWM, LLC. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Pfizer Inc. (U.S.)
• GSK plc. (U.K.)
• Merz Pharma (Germany)
• Medytox (South Korea)
• Smith+Nephew (U.S.)
• Sanofi (France)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• LGM Pharma. (U.S.)
• Lannett (U.S.)
• NorthStar Rx LLC (U.S.)

Latest Developments in Thailand Blood Plasma Market

• In October 2023, KTC Edibles, the leading provider of edible oils in the U.K., introduced Planet Palm, a fresh line of palm oil products that are certified sustainable, traceable, and sustainably produced. These products are specifically designed for food producers in the U.K.
• In September 2023, Grifols announced the expansion of its plasma collection network in North America, aiming to increase access to high-quality plasma for immunotherapy and other treatments
• In August 2023, CSL Behring launched a new high-purity immunoglobulin product, enhancing treatment options for patients with immune deficiencies and autoimmune diseases

SKU-50082